Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Gold Fields Limited (GFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Gold Fields Limited — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $287.7 (market cap $39.89B), while Gold Fields Limited trades at $33.59 (market cap $30.43B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Gold Fields Limited pays a 6.79% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | GFI | |
|---|---|---|
Market Cap | $39.89B | $30.43B |
Sector | Health | Basic Materials |
52-Week High | $491.22 | $61.52 |
52-Week Low | $278.09 | $23.95 |
Enterprise Value | $38.15B | $31.87B |
Dividend Yield | — | 6.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Gold Fields (GFI) trades at $34.14, up 0.29% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company shows strong profitability with a 40.76% net income margin and 52.33% ROE, supported by revenue growth from $5.2B in 2024 to a projected $8.8B in 2025. Recent news highlights operational challenges amid gold price volatility, with Q1 2025 production up 15% but costs rising 13% due to inflation (Seeking Alpha, 2026-06-29).
The outlook is mixed: analyst consensus is a Buy with a $53.13 price target, implying 56% upside, but technical weakness and earnings misses in Q2 and Q4 2025 pose near-term risks. Long-term value hinges on cost control and gold price stability, with debt-to-asset ratio improvements from 25.01% in 2024 to 18.27% in 2025 signaling stronger balance sheet health.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →
